Study of Obeldesivir in Children and Adolescents With COVID-19

PHASE2/PHASE3TerminatedINTERVENTIONAL
Enrollment

3

Participants

Timeline

Start Date

December 26, 2023

Primary Completion Date

February 23, 2024

Study Completion Date

February 23, 2024

Conditions
COVID-19
Interventions
DRUG

Obeldesivir

Tablet administered orally with or without food

Trial Locations (18)

13057

Child Health Care Associates, East Syracuse

29414

Velocity Clinical Research, Charleston, Charleston

32503

Avanza Medical Research Center, Pensacola

32610

UF Health- Shands Hospital, Gainesville

32829

Accel Research Sites Network - Nona Pediatric Center, Orlando

33021

Encore Medical Research LLC, Hollywood

33603

Santos Research Center, Tampa

33613

Pas Research, Tampa

35042

Trinity Clinical Research, LLC, Centreville

68134

Velocity Clinical Research, Omaha, Omaha

68701

Velocity Clinical Research, Norfolk, Norfolk

77030

Texas Children's Hospital, Houston

The University of Texas Medical School at Houston, Houston

78520

PanAmerican Clinical Research, LLC, Brownsville

87107

Velocity Clinical Research -Albuquerque, Albuquerque

89128

Pas Research, Las Vegas

92805

Advanced Research Center, Inc., Anaheim

94304

Stanford University Medical Center, Palo Alto

Sponsors

Lead Sponsor

All Listed Sponsors
lead

Gilead Sciences

INDUSTRY

NCT05996744 - Study of Obeldesivir in Children and Adolescents With COVID-19 | Biotech Hunter | Biotech Hunter